123 related articles for article (PubMed ID: 31343317)
1. Effect of diflunisal on clusterin levels in ATTRwt amyloidosis.
Torres-Arancivia C; Connors LH
Amyloid; 2019; 26(sup1):49-50. PubMed ID: 31343317
[No Abstract] [Full Text] [Related]
2. Structural studies of serum clusterin in ATTRwt amyloidosis.
Torres-Arancivia C; Chang D; Zaia J; Connors LH
Amyloid; 2019; 26(sup1):51-52. PubMed ID: 31343316
[No Abstract] [Full Text] [Related]
3. The Swedish open-label diflunisal trial (DFNS01) on hereditary transthyretin amyloidosis and the impact of amyloid fibril composition.
Wixner J; Westermark P; Ihse E; Pilebro B; Lundgren HE; Anan I
Amyloid; 2019; 26(sup1):39-40. PubMed ID: 31343354
[No Abstract] [Full Text] [Related]
4. Diflunisal compassive use in transthyretin hereditary amyloid polyneuropathy: report of a first Spanish experience.
Azorín SE; Cabib CE; Campistol JM
Amyloid; 2017 Mar; 24(sup1):105-106. PubMed ID: 28434315
[No Abstract] [Full Text] [Related]
5. Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis.
Patel RK; Fontana M; Hawkins PN; Gillmore J
Amyloid; 2021 Dec; 28(4):269-270. PubMed ID: 33945356
[No Abstract] [Full Text] [Related]
6. Inotersen treatment for ATTR amyloidosis.
Benson MD
Amyloid; 2019; 26(sup1):27-28. PubMed ID: 31343345
[No Abstract] [Full Text] [Related]
7. [Familial amyloid polyneuropathy: diflunisal].
Sekijima Y
Rinsho Shinkeigaku; 2010 Nov; 50(11):836. PubMed ID: 21921462
[No Abstract] [Full Text] [Related]
8. Assessment of the effects of transthyretin peptide inhibitors in Drosophila models of neuropathic ATTR.
Saelices L; Pokrzywa M; Pawelek K; Eisenberg DS
Neurobiol Dis; 2018 Dec; 120():118-125. PubMed ID: 30213731
[TBL] [Abstract][Full Text] [Related]
9. Evolution of amyloid fibrils in hereditary transthyretin amyloidosis: an ultrastructural study.
Koike H; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Katsuno M; Sobue G
Amyloid; 2019; 26(sup1):26. PubMed ID: 31343346
[No Abstract] [Full Text] [Related]
10. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
11. Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous.
Bezerra F; Simões CJV; Beirão JM; Saraiva MJ; Brito RMM; Almeida MR
Amyloid; 2019; 26(sup1):73-74. PubMed ID: 31343304
[No Abstract] [Full Text] [Related]
12. Two cases of late onset familial amyloid polyneuropathy with a Glu61Lys transthyretin variant.
Nakano Y; Tadokoro K; Ohta Y; Sato K; Takemoto M; Hishikawa N; Yamashita T; Yamashita T; Ando Y; Abe K
J Neurol Sci; 2018 Jul; 390():22-25. PubMed ID: 29801893
[No Abstract] [Full Text] [Related]
13. Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis.
Wixner J; Pilebro B; Lundgren HE; Olsson M; Anan I
Amyloid; 2017 Mar; 24(sup1):78-79. PubMed ID: 28042702
[No Abstract] [Full Text] [Related]
14. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy (TTR Val30Met) in a Japanese endemic area.
Takahashi R; Ono K; Shibata S; Nakamura K; Komatsu J; Ikeda Y; Ikeda T; Samuraki M; Sakai K; Iwasa K; Kayano D; Yamada M
J Neurol Sci; 2014 Oct; 345(1-2):231-5. PubMed ID: 25060417
[TBL] [Abstract][Full Text] [Related]
16. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy?
Castro J; Costa J; de Castro I; Conceição I
Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060
[No Abstract] [Full Text] [Related]
17. Quality of life assessment after 6 months of initiating treatment with tafamidis in patients with non-Val30Met mutations.
Cárdenas-Soto K; Torres-Octavo B; Mendoza-Tejeda C; Fueyo-Rodríguez O; Domínguez-Rico C; Gonzalez-Duarte A
Amyloid; 2019; 26(sup1):57-58. PubMed ID: 31343329
[No Abstract] [Full Text] [Related]
18. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
[No Abstract] [Full Text] [Related]
19. Successful use of palliative inotrope therapy in end-stage cardiac ATTR amyloidosis.
Panhwar MS; Al-Kindi S; Oliveira GH; Ginwalla M
Amyloid; 2017 Dec; 24(4):217-218. PubMed ID: 28868918
[No Abstract] [Full Text] [Related]
20. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Sekijima Y
Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
